Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

Valneva SE (“Valneva”) announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

With the U.S. FDA’s approval of Vimkunya, Bavarian Nordic A/S is now in the chikungunya virus infection mix along with Valneva SE’s Ixchiq. A single-dose, adjuvanted virus-like particle-based vaccine ...

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.